(VIANEWS) – Shares of Tilray (NASDAQ: TLRY) fell by a staggering 34.52% in 21 sessions from $2.52 at 2023-05-04, to $1.65 at 11:44 EST on Monday, after two consecutive sessions in a row of gains. NASDAQ is jumping 0.41% to $13,294.83, after two successive sessions in a row of gains.
Tilray’s last close was $1.72, 66.73% below its 52-week high of $5.17.
About Tilray
Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It offers medical and adult-use cannabis products, including GMP-certified flowers, oils, vapes, edibles, and topicals; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. The company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, P'tite Pof, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. Tilray Brands, Inc. is headquartered in Leamington, Canada.
Earnings Per Share
As for profitability, Tilray has a trailing twelve months EPS of $-2.92.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -44.15%.
Volume
Today’s last reported volume for Tilray is 7978177 which is 41.39% below its average volume of 12415800.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Tilray’s EBITDA is 2.87.
More news about Tilray (TLRY).
